To include your compound in the COVID-19 Resource Center, submit it here.

ABL bispecifics

Korean biotech ABL is developing bispecifics for cancer and Parkinson's disease

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors.

According to CEO Sang Hoon Lee, ABL001 was the first bispecific antibody to enter the clinic in South Korea; the compound is in Phase I testing for colon and ovarian cancer, as well as a third undisclosed indication. In 2Q19, ABL

Read the full 763 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE